Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-iodophenylalanine I-131
- Development stage
- Phase 1
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
A radiopharmaceutical composed of the amino acid derivative 4‑iodo‑L‑phenylalanine labeled with the beta-emitting radionuclide iodine‑131. It is designed for targeted delivery of radioactive iodine to tumor cells that take up phenylalanine analogs, enabling both imaging and therapeutic applications. The mechanism involves selective uptake by certain tumor types (notably gliomas), where the emitted beta radiation induces cytotoxicity in malignant tissue. This agent is under development primarily for use in neuro-oncology as a theranostic (diagnostic and therapeutic) tool[1][2][4][8].
- Brand names
- TLX101-TxTLX-101-TxTLX 101-Tx
- Other names
- 4-Iodophenylalanine I-1314-(131I)Iodo-L-phenylalanine4-Iodo-L-phenylalanine–131I
02
Targets
SLC7A5 (Large neutral amino acid transporter small subunit 1)
Beyond the preview
Go deeper on 4-iodophenylalanine I-131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-iodophenylalanine I-131.